Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

PURPOSE: To assess the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab). PATIENTS AND METHODS: The e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kekow, Joern, Mueller-Ladner, Ulf, Schulze-Koops, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402045/
https://www.ncbi.nlm.nih.gov/pubmed/22848150
http://dx.doi.org/10.2147/BTT.S32244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402045/
https://www.ncbi.nlm.nih.gov/pubmed/22848150
http://dx.doi.org/10.2147/BTT.S32244

Ejemplares similares